Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)

被引：0
|
作者：
Tian, Y. [1 ]
Ma, J. [2 ]
Zhu, H. [3 ]
Yu, J. [3 ]
机构：
[1] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2804
引用
收藏
页码：E360 / E360
页数：1
相关论文
共 50 条
  • [31] IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
    Reck, M.
    Liu, S. V.
    Mansfield, A. S.
    Mok, T. S. K.
    Scherpereel, A.
    Reinmuth, N.
    Garassino, M. C.
    De Castro Carpeno, J.
    Califano, R.
    Nishio, M.
    Orlandi, F.
    Alatorre Alexander, J. A.
    Leal, T. A.
    Cheng, Y.
    Lee, J-S.
    Lam, S.
    McCleland, M.
    Deng, Y.
    Phan, S.
    Horn, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 710 - +
  • [32] Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
    Bruni, A.
    Bertolini, F.
    Borghetti, P.
    Scotti, V.
    Sepulcri, M.
    Pasello, G.
    Giaj-Levra, N.
    Grisanti, S.
    Katica, M.
    Cappelli, A.
    Garlatti, P.
    Guaitoli, G.
    Dominici, M.
    Lohr, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1068 - S1068
  • [33] Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.
    Chen, Lijuan
    Zhao, Yanqiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results
    Laskin, J
    Shirley, B
    Dobbs, T
    Bi, J
    Carbone, D
    Johnson, D
    Sandler, A
    LUNG CANCER, 2005, 49 : S323 - S323
  • [35] Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
    Hu, Yi
    Chen, Jianhua
    Lv, Dongqing
    Wang, Jinliang
    Ma, Junxun
    Yi, Tienan
    Wu, Shikai
    Zhou, Xiangdong
    Zhang, Xingxing
    Chen, Dongmei
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] SERUM ALBUMIN PREDICTS OUTCOME IN PATIENTS WITH EXTENSIVE STAGE SMALL-CELL LUNG CANCER (ES-SCLC) RECEIVING FIRST-LINE COMBINATION OF PD(L)1 INHIBITORS AND PLATINUM-ETOPOSIDE CHEMOTHERAPY
    Lamberti, Giuseppe
    Ricciuti, Biagio
    Vaz, Victor
    Alessi, Joao Victor
    Pecci, Federica
    Di Federico, Alessandro
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A471 - A471
  • [37] French real world study on patient characteristics and treatment strategies in first-line of extensive-stage small cell lung cancer (ES SCLC)
    Debieuvre, D.
    Dayen, C.
    Dixmier, A.
    Gally, S.
    Pau, D.
    Greenwood, W.
    Falchero, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1038 - S1038
  • [38] Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
    O'Byrne, K. J.
    Zhang, Y.
    Ouyang, J.
    Chou, W-C.
    Chou, C-H.
    Wu, J.
    Adelakun, O.
    Hollmann, T.
    Zeng, J. A.
    Corrella, L.
    Metzler, M.
    Green, C.
    Sarmiento, R.
    Lees, E.
    Liu, Y.
    Ojalvo, L.
    Wu, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1069 - S1070
  • [39] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
    Peng, Jianfeng
    Zhang, Lemeng
    Wang, Liping
    Feng, Hui
    Yao, Dongmei
    Meng, Rui
    Liu, Xiaomei
    Li, Xiaohua
    Liu, Ningbo
    Tan, Bingxu
    Huang, Zhaoqin
    Li, Shanshan
    Meng, Xiangjiao
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [40] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
    Jianfeng Peng
    Lemeng Zhang
    Liping Wang
    Hui Feng
    Dongmei Yao
    Rui Meng
    Xiaomei Liu
    Xiaohua Li
    Ningbo Liu
    Bingxu Tan
    Zhaoqin Huang
    Shanshan Li
    Xiangjiao Meng
    Radiation Oncology, 18
12345